|
Oliver-Caldes A, Espanol-Rego M, Zabaleta A, Gonzalez-Calle V, Navarro-Velazquez S, Inoges S, de Cerio AL, Cabanas V, Lopez-Munoz N, Rodriguez-Otero P, Reguera JL, Moreno DF, Martinez-Cibrian N, Lopez-Corral L, Perez-Amill L, Martin-Antonio B, Rosinol L, Cid J, Tovar N, Saez-Penataro J, Lopez-Parra M, Olesti E, Guillen E, Varea S, Rodriguez-Lobato LG, Battram AM, Gonzalez MS, Sanchez-Salinas A, Gonzalez-Navarro A, Ortiz-Maldonado V, Delgado J, Prosper F, Juan M, Martinez-Lopez J, Moraleda JM, Mateos MV, Urbano-Ispizua A, Paiva B, Pascal M, Fernandez de Larrea C. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clin Cancer Res. 2024 May 15;30(10):2085-2096. doi: 10.1158/1078-0432.CCR-23-3759. PubMed PMID: 38466644.
AÑO: 2024; IF: 10.0
|
38466644
|
Poveda-Garcia A, Ruiz E, Moreno MJ, Espanol I, Sanchez-Salinas A, Garcia-Hernandez AM, Blanquer M, Martinez I, Sanchez-Villalobos M, Garcia Garay MC, Salido E, Heredia A, Navarro-Almenzar B, Monserrat J, Sanchez-Salas JA, Martinez-Mellado AJ, Minguela A, Campillo JA, Lopez-Hernandez R, Galian JA, Moraleda JM, Roldan V, Cabanas V. Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis. Bone Marrow Transplant. 2024 Nov;59(11):1625-1627. doi: 10.1038/s41409-024-02404-1. Epub 2024 Aug 26. No abstract available. PubMed PMID: 39187602.
AÑO: 2024; IF: 4.5
|
|
Oliver-Caldes A, Gonzalez-Calle V, Cabanas V, Espanol-Rego M, Rodriguez-Otero P, Reguera JL, Lopez-Corral L, Martin-Antonio B, Zabaleta A, Inoges S, Varea S, Rosinol L, Lopez-Diaz de Cerio A, Tovar N, Jimenez R, Lopez-Parra M, Rodriguez-Lobato LG, Sanchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Perez-Simon JA, Paiva B, Prosper F, Saez-Penataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernandez de Larrea C. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. PubMed PMID: 37414060.
AÑO: 2023; IF: 41.6
|
|
Puig N, Contreras MT, Agullo C, Martinez-Lopez J, Oriol A, Blanchard MJ, Rios R, Martin J, Inigo MB, Sureda A, Hernandez MT, de la Rubia J, Gonzalez-Calle V, Krsnik I, Cabanas V, Palomera L, Moraleda JM, Bargay J, Cedena MT, Paiva B, Rosinol L, Blade J, San Miguel J, Lahuerta JJ, Mateos MV. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv. 2022 Jun 14;6(11):3234-3239. doi: 10.1182/bloodadvances.2021006762. PubMed PMID: 35157768; PubMed Central PMCID: PMC9198943.
AÑO: 2022; IF: 7.5
|
|
Vasco-Mogorron MA, Campillo JA, Periago A, Cabanas V, Berenguer M, Garcia-Garay MC, Gimeno L, Soto-Ramirez MF, Martinez-Hernandez MD, Muro M, Minguela A. Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms. Int J Mol Sci. 2021 Apr 9;22(8):3895. doi: 10.3390/ijms22083895. PubMed PMID: 33918790; PubMed Central PMCID: PMC8068942.
AÑO: 2021; IF: 6.208
|